Introduction: New generation osmotic gradient ektacytometry has become a powerful
| INTRODUCTION
Red blood cell (RBC) membrane disorders constitute one of the major causes of chronic hereditary hemolytic anemia. Although they are worldwide distributed, their health burden vary among geographical areas depending on population ethnic background, related severity in clinical manifestations, and delay in appropriate diagnosis or misdiagnosis.
1
RBC membrane is a highly dynamic structure consisting of an outer phospholipid bilayer anchored to a spectrin-based network through two principal linking protein complexes: the ankyrin and the junctional complexes. These vertical linkages assure a strong membrane cohesion preventing membrane vesiculation, while lateral linkages between spectrin dimers and among spectrin-actin-4.1R in the junctional complex are the key regulators of membrane mechanical stability preventing membrane fragmentation [2] [3] [4] Moreover, there are various associated ion transporters, co-transporters, and channels embedded in the RBC membrane that mediates the maintenance of the cell volume and hydration status.
Main RBC membrane disorders, namely hereditary spherocytosis (HS), hereditary elliptocytosis (HE), and hereditary stomatocytosis (HSt), alter membrane cohesion, membrane mechanical stability, and RBC volume, respectively. As a consequence, RBC deformability is compromised leading to their premature removal from circulation by the spleen, manifested as hemolytic anemia.
5-8
HS and HE are RBC membrane disorders characterized by mutations in genes encoding membrane or skeletal proteins respectively, and its mutations alter the membrane complex structure. HS is the most common inherited RBC membrane disorder with one case of 2000 individuals in the Northern European countries, and probably even higher prevalence due to under diagnosis of minor or even moderate forms. The inheritance pattern is dominant in 75% of cases, and it is caused by defects in the vertical interactions that confer cohesion to the RBC membrane. [9] [10] [11] [12] HE is a common RBC hemolytic anemia, with an estimated prevalence of 3 to 5 of 10 000 individuals, although real frequency is likely to be higher due to a significant number of asymptomatic patients. HE presents an autosomal dominant inheritance, exception made for the most severe forms, named hereditary pyropoikilocytosis (HPP), which inheritance is autosomal recessive. 
21-26
Osmotic gradient ektacytometry, originally designed in the seventies, has been for many years the reference method for RBC deformability measurement but, due to its technical complexity and lack of implementation, was not used for clinical purposes. However, the new generation ektacytometer LoRRca MaxSis (Mechatronics Instruments BV ® , Zwaag, The Netherlands) has become a more robust and user friendly equipment allowing the transference from research to clinical laboratory requiring harmonization for its inclusion in the diagnostic algorithm for HS and other RBC membrane disorders. 25, 27, 28 In this study, we analyzed the differences of the several parameters obtained after performing the osmoscan module of LoRRca MaxSis among healthy controls and patients affected by HS, HE, and dHSt and determined the optimal cutoffs for HS diagnosis. The aim of this study was to evaluate the present technique as an adequate assay to perform screening of membranopathies, focusing on the differential diagnosis between HS and nonspherocytic membrane defects such as HE and dHSt.
| MATERIALS AND METHODS

| Patients and inclusion protocol
A total of 75 patients with chronic hemolytic anemia oriented as he- 
| Osmotic gradient ektacytometry
Osmotic gradient ektacytometry was performed using the osmoscan module of the Laser-assisted Optical Rotational Deformability Cell Analyzer:
LoRRca MaxSis (RR Mechatronics, The Netherlands). 34 There are several parameters defined in the osmoscan curve ( The osmoscan module of LoRRca MaxSis is performed by adding 250 uL of whole blood to 5 mL of isosmolar polyvinylpyrrolidone (iso PVP). The diluted RBC suspension is submitted to an increasing osmotic gradient (from 80 mOsmol/L to 500 mOsmol/L) under a constant shear stress of 30 mPa.
| Statistical analysis
Osmoscan parameters' statistical differences among controls and patients groups were analyzed with unpaired (two samples) t-test as
Gaussian distribution was confirmed with D'Agostino and Pearson test.
Evaluation of osmoscan parameters robustness for HS diagnosis was performed using the receiver operating characteristic (ROC)
curve analysis. The analysis compared a single HS group with a unique non-HS group that included normal controls, HE, and dHSt patients as well as with each one of these groups separately. The optimal cutoff was determined as the one with the highest likelihood ratio. Statistical analysis was operated with GraphPad Prism (GraphPad Software, La Jolla, California, USA).
| RESULTS
| Hematological parameters and HS patient's classification
Patient's general hematological data (CBC and reticulocyte count) are summarized in Table 1 .
| Hereditary spherocytosis (HS)
A total of 65 patients with HS were classified into two groups:
nonsplectomized (46 patients) and splenectomized (19 patients).
The 
| Hereditary elliptocytosis (HE)
Four of the seven patients were asymptomatic or presented very mild anemia and three showed moderate anemia. In addition, the patient with the lowest Hb concentration (86 g/L) also presented splenomegaly (echography 21 cm), reticulocytosis (7.2%). and hyperdense cells (6.1%). No HE patient underwent splenectomy.
| Dehydrated hereditary stomatocytosis (dHSt)
The 3 related patients, propositus, mother, and grandfather presented compensated chronic hemolysis associated with increased MCHC and reticulocytosis. It is worth mentioning the significant differences in clinical expression between the child, presenting with severe anemia, high reticulocytosis (15.22%), jaundice, gallstones, and early cholecystectomy (before puberty), and her relatives, who underwent cholecystectomy in adulthood. None was splenectomized.
| Osmoscan LoRRca MaxSis profiles
Specific patterns of osmoscan LoRRca MaxSis were observed for HS, HE, and dHSt ( Figure 2 ). HS curves were bell shaped, but two different profiles were identified: HS1 curves present a classical bell shape explained by an increased Omin and decreased Ohyper (moreover they present decreased EImax and AUC) and HS2 curves are moved to the right, explained by an increased Omin and also increased Ohyper (moreover they present increased Omax and decreased EImax and AUC). HE curves showed a characteristic trapezoidal shape with a decreased EImax, Omax, and AUC, with several heterogeneous profiles. dHSt curves showed a specific decrease in Ohyper and a slight increase in EImin.
The values of each osmoscan parameter obtained from the three different membrane disorders (HS, HE, and dHSt) were compared with the reference ranges established with 171 normal controls, and the observed differences were statistically analyzed (Table S1 ). The only parameter that appeared to be significantly different between normal and all membrane defects profiles was AUC. However, HS and HE profiles differed in the osmolality-related parameters (Omin, Omax, and Ohyper). Meanwhile, dHSt profile differed from HS and HE in EImax parameter.
| Osmoscan LoRRca MaxSis for HS diagnosis
To identify the most useful parameters for HS diagnosis, ROC curve analysis was performed to all the parameters that showed statistical significant differences between HS (HS1 and HS2) and non-HS (controls, HE, and dHSt): Omin, EImax, Omax, and AUC. The results showed that the best parameters were as follows: AUC (AUC 0.9903; P < .0001) and Omin (AUC 0.9642, P < .0001) and its optimal cutoff: AUC < 145.1 (sensitivity 86.15%, specificity 99.45%) and Omin > 170.5 (sensitivity 67.69%, specificity 99.45%). If the results are expressed as % of variation from the mean of normal controls, the cutoffs are less than −14.9% for AUC and more than +12.8% for
Omin.
In addition, ROC curve analysis was also performed for HS and each one of the non-HS groups separately. The results determined that EImax was the parameter that better differentiated HS from normal controls (AUC 0.9998, P < .0001) and from dHSt, while the Omin was the best parameter to separate HS from HE (AUC 0.959, P < .0001). The optimal EImax cutoff to differentiate HS from normal controls and dHSt was <0.5975 (sensitivity 98.46%, spec- for each one of the tests was analyzed (Table 2 ). In 53 HS patients, all the diagnosis tests had been performed, and in 32 of them, all the tests suggested HS. The results showed that morphology was the most sensitive test (100%) followed by LoRRca (92.5%). EMA-binding test sensitivity varied from 83.0% to 96.22% when using the threshold >−21% or >−11%, respectively.
| DISCUSSION
Osmotic gradient ektacytometry has risen during the last years, as a potential powerful technique for measuring RBC deformability 5, 6 and therefore for HS diagnosis, the most relevant RBC membrane disorder in clinical practice due to its prevalence and clinical manifestations. 6, 28 A total of 75 patients with hereditary membranopathies were included in this study: 65 HS (86.7%), 7 HE (9.3%), and 3 dHSt (4%).
Despite the low number of HE and dHSt patients, the osmotic gradient ektacytometry profiles obtained were similar to those reported so far. 28 However, these parameters are found to be highly specific but less sensitive. In our study, both parameters showed a specificity of 99.45% and a sensitivity of 86.15% for AUC As the diagnostic flow diagram for RBC membrane disorders has not yet been standardized, several HS tests have been proposed as first and second line diagnostic methods, depending on specific laboratories workflows. 5, 6, 9, 25 In this way, EMA-binding test is currently considered the first-line screening test for HS diagnosis with a reported sensitivity of 92.7% and a specificity of 99.1%. 21, 22, 36, 37 However, the cutoff point for HS diagnosis (>−21%, >−16% or >−11%)
is still a matter of debate. 21, 22, 26, 36, 38 In our study, EMA-binding sensitivity and specificity decreased to 83.0% (using the threshold >−21%) and to 96.22% (using the threshold of >−11%), respectively. However, when using the >−16% threshold, only a 5.6% of HS cases presented EMA values between 11% and 15%, and 3.8% of cases, was below 11%. Accordingly, we consider >16% the optimal EMA cutoff for HS diagnosis.
In conclusion, the combination of EMA-binding test with LoRRca T A B L E 2 Combination of HS diagnostic laboratory techniques results for HS patients
